Class Effect Is Good Enough For Boniva Ads, Judge Rules
This article was originally published in The Pink Sheet Daily
Roche/GSK advertising is not false despite lack of specific trial results for nonvertebral fractures, court says in ruling against P&G/Sanofi.
You may also be interested in...
Procter & Gamble/Sanofi-Aventis allege that Roche and GSK's campaign for Boniva is misleading because it fails to state that Boniva is not approved for treatment of nonspinal fractures.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.